Results 61 to 70 of about 10,879 (228)

NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus:Prevalence and Effect on Treatment Outcome [PDF]

, 2017
Background & Aims The efficacy of NS5A inhibitors for the treatment of patients chronically infected with hepatitis C virus (HCV) can be affected by the presence of NS5A resistance-associated substitutions (RASs).
Brainard, Diana M, Chuang, Wan-Long, Doehle, Brian, Dore, Gregory J, Dvory-Sobol, Hadas, Han, Kwang-Hyub, Hedskog, Charlotte, Jacobson, Ira, Knox, Steven, Mangia, Alessandra, Martin, Ross, McHutchison, John G, Miller, Michael D., Mizokami, Masashi, Mo, Hongmei, Pianko, Stephen, Sulkowski, Mark, Svarovskaia, Evguenia, Yun, Chohee, Zeuzem, Stefan   +19 more
core   +2 more sources

Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.

PLoS ONE, 2023
BackgroundInsurers manage the cost of specialty medicines via rebates, however it is unclear if the savings are passed on to patients, and whether reducing rebates may lead to changes in patient out-of-pocket (OOP) costs and medication adherence.
William Bruce Wong, Arpamas Seetasith, Anna Hung, Leah L Zullig   +3 more
doaj   +3 more sources

Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years

Medicina
Background and Objectives: Chronic hepatitis C (CHC) can be cured with direct-acting antiviral (DAA) therapy. In Korea, sofosbuvir (SOF) and ledipasvir (LDV)/SOF were launched in 2016.
Yewan Park, Seong-Kyun Na, Jae-Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Gi-Ae Kim, Hyo-Young Lee, Young-Sun Lee, Jeong-Han Kim   +8 more
doaj   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents [PDF]

, 2017
Hepatitis C virus (HCV) chronic infection can be associated with extrahepatic manifestations such as mixed cryoglobulinaemia and lymphoproliferative disorders that are endowed with increased rates of morbidity and all-cause mortality.
Burra, Patrizia, Farinati, Fabio, Floreani, Annarosa, Fogar, Paola, Franceschet, Enrica, Gambato, Martina, Nabergoj, Mitja, Pantano, G, Piva, Elisa, Plebani, Mario, Russo, FRANCESCO PAOLO, Schiavinato, Alvise, Tosato, Francesca, Zanetto, Alberto   +13 more
core   +1 more source

Post‐to Pretreatment Ratio of Serum CXCL10 Level Predicts Short‐Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct‐Acting Antiviral Therapy

Hepatology Research, EarlyView.
The post‐to pretreatment serum CXCL10 ratio was independently associated with short‐term liver function outcome following HCV eradication in cirrhotic patients. ABSTRACT Aim The prognostic value of serum C‐X‐C motif chemokine ligand 10 (CXCL10) levels for liver function was investigated in hepatitis C virus (HCV)–infected patients with compensated or ...
Takanori Suzuki, Kentaro Matsuura, Yuki Tahata, Hayato Hikita, Masaru Enomoto, Atsunori Tsuchiya, Daiki Miki, Hiroshi Yatsuhashi, Hidekatsu Kuroda, Taro Yamashita, Hitoshi Yoshiji, Nobuharu Tamaki, Seiichi Mawatari, Hisamitsu Miyaaki, Yasuhiro Asahina, Yoichi Hiasa, Yoshihito Uchida, Yasunari Nakamoto, Taro Takami, Takahiro Kodama, Tetsuo Takehara   +20 more
wiley   +1 more source

The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.

PLoS ONE, 2021
BackgroundSofosbuvir and ledipasvir-sofosbuvir are both newer direct-acting antiviral agents for the treatment of hepatitis C. The high list prices for both drugs have led to concern about the budget impact for public drug coverage programs.
Harriet Ho, Naveed Z Janjua, Kimberlyn M McGrail, Mark Harrison, BC Hepatitis Testers Cohort Team, Michael R Law   +5 more
doaj   +1 more source

Pre‐Treatment Liver Stiffness Is a Stronger Predictor of Hepatocellular Carcinoma Development Than Post‐Treatment Liver Stiffness After Hepatitis C Virus Eradication

Hepatology Research, Volume 56, Issue 2, Page 161-171, February 2026.
Higher pre‐treatment liver stiffness measurement (LSM) values, rather than post‐treatment values, independently predicts hepatocellular carcinoma after hepatitis C virus eradication, underscoring the need for continued surveillance in patients with elevated baseline LSM.
Takuma Nakatsuka, Ryo Nakagomi, Keisuke Mabuchi, Yuki Matsushita, Tomoharu Yamada, Kazuya Okushin, Tatsuya Minami, Masaya Sato, Koji Uchino, Yotaro Kudo, Mitsuhiro Fujishiro, Kazuhiko Koike, Ryosuke Tateishi   +12 more
wiley   +1 more source

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced

Gut and Liver, 2017
Background/AimsChronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia.Methods : Patients (n=30) were enrolled between September 2015 and April 2016.
Hyun Woong Lee, Ki Young Yoo, Joung Won Won, Hyung Joon Kim   +3 more
doaj   +1 more source

A hepatitis C-vírus-fertőzés és kezelésének költségvonzata [PDF]

, 2015
Absztrakt A hepatitis C-vírus-fertőzés a Föld lakosságának 2–3%-át érinti és a betegséghez társuló egyéni következmények mellett igen jelentős össztársadalmi gazdasági problémát jelent.
Hunyady, Béla, Makara, Mihály
core   +1 more source